| LENZ Therapeutics, Inc. (LENZ) Q1 2025 Earnings Call Transcript |
LENZ Therapeutics, Inc. (NASDAQ:LENZ ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Dan Chevallard - Chief Financial Officer Eef Schimmelpennink - President & Chief Executive Officer Shawn Olsson - Chief Commercial Officer Marc Odrich - Chief Medical Officer Conference Call Participants Stacy Ku - TD Cowen Pawan Patel - Bank of America Yigal Nochomovitz - Citi Lachlan Hanbury-Brown - William Blair Denis Reznik - Raymond James Matthew Caufield - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the LENZ Therapeutics First Quarter 2025 Financial Results Conference Call. |
seekingalpha.com |
2025-05-09 14:33:15 |
Czytaj oryginał (ang.) |
| LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia |
SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSW Stock Code: 1795) today announced an exclusive license and commercialization agreement for Lotus to commercialize LNZ100 for the treatment of presbyopia in the Republic of Korea and certain countries in Southeast Asia. |
globenewswire.com |
2025-05-09 13:03:00 |
Czytaj oryginał (ang.) |
| LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights |
New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 |
globenewswire.com |
2025-05-07 20:05:00 |
Czytaj oryginał (ang.) |
| LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference |
SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in a fireside chat and one-on-one meetings at the BofA Securities 2025 Health Care Conference taking place May 13- 15, 2025 in Las Vegas, NV. |
globenewswire.com |
2025-05-06 20:30:00 |
Czytaj oryginał (ang.) |
| LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025 |
SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, May 7th, 2025, at 4:30 p.m. EDT to report its first quarter 2025 financial results and recent corporate highlights. |
globenewswire.com |
2025-04-30 20:30:00 |
Czytaj oryginał (ang.) |
| LENZ Therapeutics: Freedom From Reading Glasses |
LENZ Therapeutics' LNZ100 for presbyopia is in an advanced approval phase, targeting a $3B+ market, with potential U.S. launch in 2025. With $209.1M in cash and no debt, LENZ is expected to reach positive cash flow in 2027-2028. A base-case Fair Value estimate is $42.55, indicating a 101% potential upside; while in an optimistic scenario with international expansion, the Fair Value estimate is $55.5, reflecting a 162% potential upside. |
seekingalpha.com |
2025-04-07 12:00:00 |
Czytaj oryginał (ang.) |
| LENZ Therapeutics Stock Is Attractive Before PDUFA |
LENZ Therapeutics, Inc.'s LNZ100 eye drop shows promising results for presbyopia, with strong phase 3 data and potential FDA approval by August 2025. LNZ100 demonstrated superior efficacy compared to AbbVie's Vuity, with a broad patient range and rapid onset of treatment effect. Survey data indicates high interest among eye care professionals, with 82% likely to prescribe LNZ100 if approved, targeting a $3bn market. |
seekingalpha.com |
2025-03-27 19:33:11 |
Czytaj oryginał (ang.) |
| LENZ Therapeutics, Inc. (LENZ) Q4 2024 Earnings Call Transcript |
LENZ Therapeutics, Inc. (NASDAQ:LENZ ) Q4 2024 Results Conference Call March 19, 2025 4:30 PM ET Company Participants Dan Chevallard - Chief Financial Officer Eef Schimmelpennink - President & Chief Executive Officer Shawn Olsson - Chief Commercial Officer Marc Odrich - Chief Medical Officer Conference Call Participants Yigal Nochomovitz - Citigroup Madhu Yennawar - Leerink Partners Joe Catanzaro - Piper Sandler Stacy Ku - TD Cowen Jason Gerberry - Bank of America Lachlan Hanbury-Brown - William Blair Denis Reznik - Raymond James Matthew Caufield - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to the LENZ Therapeutics Year End 2024 Financial Results Conference Call. |
seekingalpha.com |
2025-03-19 22:09:03 |
Czytaj oryginał (ang.) |
| LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights |
New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 |
globenewswire.com |
2025-03-19 18:05:00 |
Czytaj oryginał (ang.) |
| LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025 |
SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, March 19, 2025, at 4:30 p.m. EST to report its fourth quarter and full year 2024 financial results and recent corporate highlights. |
globenewswire.com |
2025-03-11 10:00:00 |
Czytaj oryginał (ang.) |
| LENZ Therapeutics to Host Commercial Day on April 15, 2025 |
SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that it will host a Commercial Day to highlight the commercialization strategy and progress towards the potential approval of LNZ100 for the treatment of presbyopia. The event will take place on Tuesday, April 15, 2025, from 2:00 p.m. |
globenewswire.com |
2025-03-03 10:00:00 |
Czytaj oryginał (ang.) |
| LENZ Therapeutics to Participate in Upcoming Investor Conferences |
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in the following upcoming investor conferences: |
globenewswire.com |
2025-02-24 10:00:00 |
Czytaj oryginał (ang.) |
| Here's Why LENZ Therapeutics, Inc. (LENZ) Is a Great 'Buy the Bottom' Stock Now |
After losing some value lately, a hammer chart pattern has been formed for LENZ Therapeutics, Inc. (LENZ), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term. |
zacks.com |
2024-11-18 12:55:35 |
Czytaj oryginał (ang.) |
| LENZ Therapeutics to Participate in Upcoming Investor Conferences |
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in the following upcoming investor conferences: |
globenewswire.com |
2024-11-12 10:00:00 |
Czytaj oryginał (ang.) |
| LENZ Therapeutics, Inc. (LENZ) Is Up 3.37% in One Week: What You Should Know |
Does LENZ Therapeutics, Inc. (LENZ) have what it takes to be a top stock pick for momentum investors? Let's find out. |
zacks.com |
2024-11-11 15:06:18 |
Czytaj oryginał (ang.) |
| LENZ Therapeutics, Inc. (LENZ) Q3 2024 Earnings Call Transcript |
LENZ Therapeutics, Inc. (NASDAQ:LENZ ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Dan Chevallard - CFO Eef Schimmelpennink - President and CEO Shawn Olsson - CCO Marc Odrich - CMO Conference Call Participants Yigal Nochomovitz - Citi Marc Goodman - Leerink Partners Joe Catanzaro - Piper Sandler Pavan Patel - Bank of America Lachlan Hanbury-Brown - William Blair Gary Nachman - Raymond James Matthew Caufield - H. C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to the LENZ Therapeutics' Third Quarter 2024 Conference Call. |
seekingalpha.com |
2024-11-06 13:43:30 |
Czytaj oryginał (ang.) |
| LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships |
On Sunday, Corxel Pharmaceuticals and LENZ Therapeutics LENZ released topline data from the Phase 3 JX07001 trial of LNZ100 in patients with presbyopia in China. |
benzinga.com |
2024-10-28 15:51:11 |
Czytaj oryginał (ang.) |
| CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100 |
Primary endpoint was met with 74% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours post treatment，and maintaining their optimal distance visual acuity (i.e., not losing 5 or more letters). The difference in efficacy was statistically significant in the LNZ100 treatment group compared to the vehicle group (p |
globenewswire.com |
2024-10-27 23:00:00 |
Czytaj oryginał (ang.) |
| LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia |
FDA sets Prescription Drug User Fee Act (PDUFA) target date of August 8, 2025 FDA sets Prescription Drug User Fee Act (PDUFA) target date of August 8, 2025 |
globenewswire.com |
2024-10-21 12:00:00 |
Czytaj oryginał (ang.) |
| LENZ Therapeutics: Upcoming PDUFA, Strong Data, Some Risks |
Graphite Bio reverse merged with Lenz Therapeutics to focus on presbyopia, a $3bn+ market impacting 1.8 billion people globally. LNZ100, a 1.75% Aceclidine eye drop solution, conducted two positive phase 3 clinical trials for presbyopia, showing promising results. LENZ has a market cap of $617mn, cash balance of $226mn, submitted an NDA in August, and has $500mn peak sales estimate. |
seekingalpha.com |
2024-08-30 12:00:00 |
Czytaj oryginał (ang.) |
| LENZ Therapeutics to Participate in Upcoming Investor Conferences |
SAN DIEGO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first and only aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced that company management will participate in the following upcoming investor conferences: |
globenewswire.com |
2024-08-27 20:01:00 |
Czytaj oryginał (ang.) |
| LENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024 |
LENZ Therapeutics (NASDAQ: LENZ ) just reported results for the first quarter of 2024. LENZ Therapeutics reported earnings per share of -$3.53. |
investorplace.com |
2024-08-26 06:22:41 |
Czytaj oryginał (ang.) |
| LENZ Therapeutics, Inc. (LENZ) Q2 2024 Earnings Call Transcript |
LENZ Therapeutics, Inc. (NASDAQ:LENZ ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Dan Chevallard - CFO Eef Schimmelpennink - President & CEO Shawn Olsson - Chief Commercial Officer Marc Odrich - Chief Medical Officer Conference Call Participants Pavan Patel - Bank of America Yigal Nochomovitz - Citigroup Joseph Catanzaro - Piper Sandler Marc Goodman - Leerink Lachlan Hanbury-Brown - William Blair Matthew Caufield - H. C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the LENZ Therapeutics Second Quarter 2024 Conference Call. |
seekingalpha.com |
2024-08-16 23:43:07 |
Czytaj oryginał (ang.) |
| LENZ Therapeutics Reports Second Quarter 2024 Financial Results |
Submitted New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for LNZ100 for the treatment of presbyopia |
globenewswire.com |
2024-08-14 20:05:00 |
Czytaj oryginał (ang.) |
| LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia |
SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that the Company has submitted a New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for LNZ100 (an aceclidine-based ophthalmic solution) for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. |
globenewswire.com |
2024-08-12 12:00:00 |
Czytaj oryginał (ang.) |
| LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024 |
SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, August 14, 2024 at 4:30 p.m. ET to report its second quarter 2024 financial results and provide a business update. |
globenewswire.com |
2024-08-07 20:01:00 |
Czytaj oryginał (ang.) |
| LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024 |
Capstone data from Phase 3 CLARITY study to be presented Event to feature Key Opinion Leader and Principal Investigator perspectives on LNZ100 potential in presbyopia SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that the Company will host a Key Opinion Leader (“KOL”) event on Tuesday, June 18, 2024 at 8:00 a.m. ET. The event will highlight real-world insights by Key Opinion Leaders and Principal Investigators on the current treatment landscape for presbyopia and their perspectives on LNZ100 data from the Phase 3 CLARITY study. |
globenewswire.com |
2024-06-10 12:00:00 |
Czytaj oryginał (ang.) |
| LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference |
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced that Eef Schimmelpennink, President and Chief Executive Officer, will present and company management will participate in one-on-one meetings at the Jefferies Global Healthcare Conference being held from June 5th- 6th, 2024 in New York City. |
globenewswire.com |
2024-05-30 12:00:00 |
Czytaj oryginał (ang.) |
| LENZ Therapeutics, Inc. (LENZ) Q1 2024 Earnings Call Transcript |
LENZ Therapeutics, Inc. (NASDAQ:LENZ ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Dan Chevallard - Chief Financial Officer Eef Schimmelpennink - President and CEO Dr. Marc Odrich - Chief Medical Officer Shawn Olsson - Chief Commercial Officer Conference Call Participants Joseph Catanzaro - Piper Sandler Yigal Nochomovitz - Citigroup Tim Lugo - William Blair Basma Radwan - Leerink Partners Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to LENZ Therapeutics First Quarter 2024 Financial Results and Business Update. |
seekingalpha.com |
2024-05-11 11:26:09 |
Czytaj oryginał (ang.) |
| LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates |
Reported positive topline data from Phase 3 CLARITY study for presbyopia; selected LNZ100 as lead candidate; New Drug Application submission anticipated in mid-2024 |
globenewswire.com |
2024-05-08 20:01:00 |
Czytaj oryginał (ang.) |
| LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024 |
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, May 8, 2024 at 4:30 p.m. ET to report its first quarter 2024 financial results and provide a business update. |
globenewswire.com |
2024-05-01 20:01:00 |
Czytaj oryginał (ang.) |
| Lenz Therapeutics' eye disease drugs meet main goal of late-stage study |
Lenz Therapeutics said on Wednesday its experimental drugs to treat loss of near vision met the main goal of a late-stage study, sending its shares up nearly 23% before the bell. |
reuters.com |
2024-04-03 11:49:58 |
Czytaj oryginał (ang.) |